Intriguing new tech from up-and-coming device firms

Despite the venture capital challenges facing start-up medical technology companies, some have managed to develop intriguing new devices and diagnostics. Here are 5 to watch. Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.